000272896 001__ 272896
000272896 005__ 20241117000023.0
000272896 0247_ $$2doi$$a10.1093/neuonc/noae092
000272896 0247_ $$2pmid$$apmid:38835160
000272896 0247_ $$2pmc$$apmc:PMC11534318
000272896 0247_ $$2ISSN$$a1522-8517
000272896 0247_ $$2ISSN$$a1523-5866
000272896 0247_ $$2altmetric$$aaltmetric:164222919
000272896 037__ $$aDZNE-2024-01308
000272896 041__ $$aEnglish
000272896 082__ $$a610
000272896 1001_ $$00000-0003-3302-2719$$aMynarek, Martin$$b0
000272896 245__ $$aRisk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa-Results of the HIT 2000 trial.
000272896 260__ $$aOxford$$bOxford Univ. Press$$c2024
000272896 3367_ $$2DRIVER$$aarticle
000272896 3367_ $$2DataCite$$aOutput Types/Journal article
000272896 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1731405238_14056
000272896 3367_ $$2BibTeX$$aARTICLE
000272896 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272896 3367_ $$00$$2EndNote$$aJournal Article
000272896 520__ $$aNeurocognition can be severely affected in pediatric brain tumor survivors. We analyzed the association of cognitive functioning with radiotherapy dose, postoperative cerebellar mutism syndrome (pCMS), hydrocephalus, intraventricular methotrexate (MTX) application, tumor localization, and biology in pediatric survivors of a posterior fossa tumor.Subdomain-specific neurocognitive outcome data from 279 relapse-free survivors of the HIT-2000 trial (241 medulloblastoma and 38 infratentorial ependymoma) using the Neuropsychological Basic Diagnostic tool based on Cattell-Horn-Carroll's model for intelligence were analyzed.Cognitive performance 5.14 years (mean; range = 1.52-13.02) after diagnosis was significantly below normal for all subtests. Processing speed and psychomotor abilities were most affected. Influencing factors were domain-specific: CSI-dose had a strong impact on most subtests. pCMS was associated with psychomotor abilities (β = -0.25 to -0.16) and processing speed (β = -0.32). Postoperative hydrocephalus correlated with crystallized intelligence (β = -0.20) and short-term memory (β = -0.15), age with crystallized intelligence (β = 0.15) and psychomotor abilities (β = -0.16 and β = -0.17). Scores for fluid intelligence (β = -0.23), short-term memory (β = -0.17) and visual processing (β = -0.25) declined, and scores for selective attention improved (β = 0.29) with time after diagnosis.The dose of CSI was strongly associated with neurocognitive outcomes. Low psychomotor abilities and processing speed both in patients treated with and without CSI suggest a strong contribution of the tumor and its surgery on these functions. Future research therefore should analyze strategies to both reduce CSI dose and toxicity caused by other treatment modalities.
000272896 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272896 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272896 650_7 $$2Other$$aependymoma
000272896 650_7 $$2Other$$ainfant
000272896 650_7 $$2Other$$amedulloblastoma
000272896 650_7 $$2Other$$aneuropsychological late effects
000272896 650_7 $$2Other$$aquality of survival
000272896 650_2 $$2MeSH$$aHumans
000272896 650_2 $$2MeSH$$aChild
000272896 650_2 $$2MeSH$$aFemale
000272896 650_2 $$2MeSH$$aMale
000272896 650_2 $$2MeSH$$aInfratentorial Neoplasms: therapy
000272896 650_2 $$2MeSH$$aAdolescent
000272896 650_2 $$2MeSH$$aChild, Preschool
000272896 650_2 $$2MeSH$$aMedulloblastoma: therapy
000272896 650_2 $$2MeSH$$aRisk Factors
000272896 650_2 $$2MeSH$$aEpendymoma: therapy
000272896 650_2 $$2MeSH$$aNeuropsychological Tests
000272896 650_2 $$2MeSH$$aCancer Survivors: psychology
000272896 650_2 $$2MeSH$$aCancer Survivors: statistics & numerical data
000272896 650_2 $$2MeSH$$aFollow-Up Studies
000272896 650_2 $$2MeSH$$aHydrocephalus: etiology
000272896 650_2 $$2MeSH$$aCognition Disorders: etiology
000272896 650_2 $$2MeSH$$aPrognosis
000272896 650_2 $$2MeSH$$aMutism: etiology
000272896 7001_ $$aRossius, Anne$$b1
000272896 7001_ $$aGuiard, Anika$$b2
000272896 7001_ $$aOttensmeier, Holger$$b3
000272896 7001_ $$avon Hoff, Katja$$b4
000272896 7001_ $$aObrecht-Sturm, Denise$$b5
000272896 7001_ $$00000-0003-3888-1360$$aBußenius, Lisa$$b6
000272896 7001_ $$aFriedrich, Carsten$$b7
000272896 7001_ $$00000-0003-4197-6264$$avon Bueren, Andre O$$b8
000272896 7001_ $$aGerber, Nicolas U$$b9
000272896 7001_ $$aTraunwieser, Thomas$$b10
000272896 7001_ $$00000-0002-8952-1819$$aKortmann, Rolf-Dieter$$b11
000272896 7001_ $$00000-0002-3544-319X$$aWarmuth-Metz, Monika$$b12
000272896 7001_ $$aBison, Brigitte$$b13
000272896 7001_ $$aThomale, Ulrich-W$$b14
000272896 7001_ $$aKrauss, Juergen$$b15
000272896 7001_ $$0P:(DE-2719)2812617$$aPietsch, Torsten$$b16$$udzne
000272896 7001_ $$aClifford, Steven C$$b17
000272896 7001_ $$aPfister, Stefan M$$b18
000272896 7001_ $$aSturm, Dominik$$b19
000272896 7001_ $$00000-0001-5441-1962$$aSahm, Felix$$b20
000272896 7001_ $$aTischler, Tanja$$b21
000272896 7001_ $$00000-0002-5446-9571$$aRutkowski, Stefan$$b22
000272896 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae092$$gVol. 26, no. 11, p. 2113 - 2124$$n11$$p2113 - 2124$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
000272896 8564_ $$uhttps://pub.dzne.de/record/272896/files/DZNE-2024-01308_Restricted.pdf
000272896 8564_ $$uhttps://pub.dzne.de/record/272896/files/DZNE-2024-01308_Restricted.pdf?subformat=pdfa$$xpdfa
000272896 909CO $$ooai:pub.dzne.de:272896$$pVDB
000272896 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812617$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000272896 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272896 9141_ $$y2024
000272896 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000272896 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000272896 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000272896 9201_ $$0I:(DE-2719)1011009$$kBrainbank (Bonn)$$lBrainbank Unit Bonn$$x0
000272896 980__ $$ajournal
000272896 980__ $$aVDB
000272896 980__ $$aI:(DE-2719)1011009
000272896 980__ $$aUNRESTRICTED